[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353143-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353143-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","predicting-prognosis-and-drug-sensitivity-in-patients-with-hepatocellular-carcinoma-using-an-lncrna-signature-associated-with-cuproptosis","Predicting prognosis and drug sensitivity in patients with hepatocellular carcinoma using an lncRNA signature associated with cuproptosis","","Hepatocellular carcinoma is a highly aggressive malignancy, and the molecular drivers of its progression and therapeutic response remain unclear. Cuproptosis, linked to disrupted copper homeostasis, motivates the development of a prognostic and therapy-oriented long non-coding RNA signature. Using TCGA transcriptome and clinical data, a five-lncRNA CRlncRNA panel is built for survival prediction and drug-sensitivity estimation, then supported by differential expression validation and in vitro functional testing of LINC02505.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/predicting-prognosis-and-drug-sensitivity-in-patients-with-hepatocellular-carcinoma-using-an-lncrna-signature-associated-with-cuproptosis/353143/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/predicting-prognosis-and-drug-sensitivity-in-patients-with-hepatocellular-carcinoma-using-an-lncrna-signature-associated-with-cuproptosis/353143.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study on hepatocellular carcinoma?","Question",{"text":63,"@type":64},"To develop a cuproptosis-related lncRNA signature that predicts prognosis and drug sensitivity in patients with hepatocellular carcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the CRlncRNA signature constructed?",{"text":68,"@type":64},"Transcriptome and clinical data were retrieved from TCGA, and the five prognostic lncRNAs were selected using co-expression analysis, Lasso Cox regression, and univariate and multivariate Cox regression.",{"name":70,"@type":61,"acceptedAnswer":71},"How was drug sensitivity evaluated in relation to the lncRNA signature?",{"text":72,"@type":64},"The signature’s association with the efficacy of chemotherapy and targeted drugs was assessed, and IC50 was used to estimate drug sensitivity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353143,1790211029,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4398046744996,"Li etal. BMC Cancer (2026) 26:762 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16132-w](https://doi.org/10.1186/s12885-026-16132-w)  \nRESEARCH Open Access  \nPredicting prognosis and drug sensitivity in patients with hepatocellular carcinoma using an lncRNA signature associated with cuproptosis  \nYan Li1, Shiyu Lv1 andYunqiu Wang1*  \nAbstract  \nBackground Hepatocellular carcinoma (HCC) is a prevalent type of malignant tumor known for its aggressive proliferation and invasive behavior. The exact molecular mechanisms underlying HCC development and progression remain unclear. Nevertheless, cuproptosis has been linked to a range of diseases, including cancers, resulting from imbalances in copper homeostasis. Here, a unique signature of long non-coding RNAs (lncRNAs) was developed, known as cuproptosis-related lncRNA (CRlncRNA) . This signature has significant value in clinical practice for predicting prognosis and drug sensitivity in individuals with HCC.  \nMethods The transcriptome data and clinical information were retrieved from the Cancer Genome Atlas (TCGA) database. The independent prognostic signature of five CRlncRNAs was constructed by co-expression analysis, Lasso Cox regression analysis, and univariate and multivariate Cox regression analysis. K-M analysis and ROC curve were used to evaluate the effectiveness of the signature in predicting prognosis and IC50 was used to predict the sensitivity of drugs. Furthermore, the differential expression of five CRlncRNAs was validated in clinical HCC samples, and functional in vitro experiments were performed to investigate the biological role of LINC02505, which is one of the five CRlncRNAs.  \nResults Based on 374 HCC samples, a prognostic risk signature of five lncRNAs was constructed. High-risk patients showed significantly decreased survival periods, indicating that the CRlncRNA signature has predictive value in HCC. Combined with clinical and pathological information, the signature was shown to be an independent prognostic factor. Besides, the CRlncRNA signature was found to be closely associated with the efficacy of many commonly used chemotherapy drugs and targeted drugs for HCC patients. Additionally, further investigations showed that the mutation rate of HCC was related to the CRlncRNA signature, and gene enrichment analysis focused on immunerelated pathways. Finally, among the CRlncRNA signature, LINC02505 was tested as a risk factor in vitro.  \nConclusions The CRlncRNA signature has significant clinical implications as it offers new biomarkers for evaluating HCC prognosis and guiding clinical medication.  \n*Correspondence:  \nYunqiu Wang [wangyunqiu@sdfmu.edu.cn](wangyunqiu@sdfmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLi et al. BMC Cancer (2026) 26:762 Page 2 of 17  \nKeywords Hepatocellular carcinom","cbCaiq4fw4HedROF","https://ap.wps.com/l/cbCaiq4fw4HedROF","pdf",9910991,17,"English","# Abstract\n# Introduction\n## Epidemiology and risk factors\n## Limits of current treatments\n## Role of lncRNAs and noncoding RNAs\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the main goal of the study on hepatocellular carcinoma?\",\"answer\":\"To develop a cuproptosis-related lncRNA signature that predicts prognosis and drug sensitivity in patients with hepatocellular carcinoma.\"},{\"question\":\"How was the CRlncRNA signature constructed?\",\"answer\":\"Transcriptome and clinical data were retrieved from TCGA, and the five prognostic lncRNAs were selected using co-expression analysis, Lasso Cox regression, and univariate and multivariate Cox regression.\"},{\"question\":\"How was drug sensitivity evaluated in relation to the lncRNA signature?\",\"answer\":\"The signature’s association with the efficacy of chemotherapy and targeted drugs was assessed, and IC50 was used to estimate drug sensitivity.\"}]","Predicting prognosis and drug sensitivity in patients with hepatocellular carcinoma using an lncRNA signature associated with cuproptosis | PDF",1790103284,43,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59afca66690f1d811588ca38337e03de.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8dd22ee02fc0cf26b6eb01bc8451328e.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/025532d60734691c2160548e1c220d74.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78f5b473eea06c85618bf1018ade6fc6.webp",980,1306]